The hypolipidemic activity of the phenolic ether, 2-methyl-2-[p-(1,2,3,4-tetrahydro-1naphthyl)-phenoxy]-propionic acid (Su-13437, Ciba) has been studied in 10 hypercholesterolemic patients. The patients were studied at 3-week intervals during 30 weeks of placebo administration and a 30-week period of treatment with Su-13437, 400 mg daily.
T HE phenolic ether, 2-methyl-2-[p- ( 1,2,3, 4-tetrahydro-1-naphthyl) -phenoxy] -propionic acid (Su-13437) ( fig. 1 ) was reported in 1968 by Hess and Bencze to possess hypolipidemic activity in the rat.' Initial clinical trials have indicated that this drug also lowers the concentrations of serum cholesterol and triglyceride in man.24 The encouraging lack of serious adverse effects observed in these trials prompted us to undertake a comparison of Su-13437 and a placebo, each administered for 30 weeks to 10 hyperlipidemic subjects. Special attention was directed to Hypertriglyceridemia the previously noted effects of the drug on certain serum enzymes as well as on serum lipids.3 4 
Methods
The 10 subjects (table 1) had been under outpatient observation for periods of 1 to 11 years before this study and had demonstrated their ability and willingness to cooperate. Prior to this study all had received ethyl chlorophenoxyisobutyrate (CPIB) for at least 6 mo, and eight of the 10 had received Su-13437 for 8 weeks in a preliminary study of the effects of the drug on serum lipids.2 None had taken serum lipidlowering drugs for periods of 4 to 58 weeks (mean, 24 weeks) prior to the initial placebo period. Most of the patients had sustained myocardial infarctions, all at least 1 year prior to this study. Only one subject (patient 9) was considered to be a diabetic, and she was maintained on phenformin, 50 mg daily, throughout placebo and treatment periods. None had hyperlipoproteinemia secondary to other diseases, nor were any taking anticoagulant or anovulatory drugs. The total period of study was 60 weeks. A placebo tablet resembling the active drug was administered for the first 15 weeks, Su-13437, 100 mg four times daily, for the next 30 weeks, and finally the placebo again for the last 15 weeks. At the start of the study the subjects were advised not to modify their current diets or any customary moderate consumption of alcohol. Subjects 1 and 2 reported fair adherence to the restricted cholesterol and modified fat diet recommended in the American Heart Association's booklet "Planning Fat-Controlled Meals" which they had followed for several years. Following the detection of diabetes mellitus 15 mo before this study, subject 9 had followed a diet restricted in calories which had resulted in a weight loss of 15 pounds during the first 3 mo and stable weight thereafter. For the period immediately prior to and during this study the remaining seven subjects used free diets. The investigators but not the patients were aware of the time of the change from placebo to active drug and back to placebo. The nature of the study was explained to each patient, and participation was entirely voluntary.
The patients were seen at 3-week intervals throughout the study so that a total of 10 observations were made during the administration of placebo and a like number during treatment with Su-13437. At each visit body weight and blood pressure were recorded, and interval medical history was noted. After an overnight fast of approximately 14 hours venous blood was collected, allowed to clot at room temperature for 20 minutes, and the serum was separated by centrifugation. Hematocrit, total and differential white blood cell count, and urinalysis were performed at each visit. Concentrations of serum total cholesterol, triglyceride, creatinine phosphokinase, glutamic oxalacetic transaminase (SGOT), and glutamic pyruvic transaminase (SGPT) were also determined at each visit.
Serum urea nitrogen, uric acid, and total bilirubin were measured at altemate visits. Determinations of serum protein-bound iodine and resin triiodothyronine 131l uptake were performed once during the initial placebo period and again at the final treatment visit.
Serum total cholesterol was determined in duplicate by the method of Abell and associates5 and serum triglyceride, also in duplicate, by the previously described modification6 of the method of Van Handel and Zilversmit.7 As a measure of the reproducibility of the serum lipid analyses a specimen from a single lot of reconstituted lyophilized human serum was included in each lot of patient sera analyzed. Ninety-eight determina-
Su-1 3437 (nafenopin, Ciba) and CPIB (clofibrate, Ayerst).
Circulation, Volume XLII, November 1970 tions of total cholesterol of the pooled serum resulted in a 1.7% average deviation from the mean (range, -6.5% to +4.9%). Sixty-two determinations of triglyceride resulted in a 3.2% average deviation from the mean (range, -8.8% to +10.4%).
Creatine phosphokinase was determined by a colorimetric method (Sigma) with inorganic phosphorus being determined by the method of Fiske and SubbaRow. SGOT and SGPT were determined colorimetrically.8 Serum urea nitrogen, uric acid, total bilirubin, protein-bound iodine, and resin triiodothyronine 131I uptake were performed by Biochemical Procedures, North Hollywood, California.
Results
All of the subjects were hypercholesterolemic, the individual mean serum cholesterol levels during placebo administration ranging from 255 to 609 mg/ 100 ml (table 2). There was no consistent difference between the two placebo periods, but serum cholesterol was significantly lower in all patients during administration of Su-13437 (P < 0.01). The . 12 24 Time (weeks) Figure 3 Efect of Su-13437 on SGOT levels. T of the increased levels in subjects illustrated. The solid line indicates th level of the eight subjects who exhibit in SGOT. treatment ( fig. 2 ). There was nc difference between the mean sen ol response of the six subjects hyperlipoproteinemia and that four subjects, the responses of th being essentially parallel if plotte Three weeks after the substitutio for the active drug the mean serui level had returned to its pretreatif Five of the 10 subjects hypertriglyceridemic, having indi serum triglyceride levels duri administration ranging from 1 mg/ 100 ml. The remaining five individual mean serum triglyceride levels of less than 150 mg/ 100 ml. In each of the five subjects with increased triglyceride levels Su-13437 resulted in a significant reduction (P < 0.001). As with cholesterol, serum triglyceride levels declined sharply during the first 3 weeks of Su-13437 administration, maintained the reduced levels for the duration of treatment, and with the substitution of placebo for the active drug returned to or slightly above the pretreatment range. Of the = <°five subjects with normal serum triglyceride 36 48 levels, four also responded to Su-13437 with significant reductions (P < 0.05). administration, the levels returning to the pretreatment values despite continuation of the drug. Subject 5 displayed more marked and more persistent elevations of SGOT and SGPT levels, her values returning to the pretreatment level only after discontinuation of Su-13437.
Su
Comparison of the mean levels of serum cholesterol during treatment with Su-13437, 400 mg/day, in this study with the mean levels previously observed in the same subjects during treatment with CPIB, 2 g/day, reveals no consistent differences in the responses to the two drugs ( fig. 5 ). In the entire group of subjects the mean reduction in serum cholesterol was 18% with CPIB and 22% with Su-13437. At the doses employed Su-13437 had somewhat greater effect than CPIB on serum triglyceride. In the five hypertriglyceridemic patients the mean reduction was 28% with CPIB and 51% with Su-13437.
Discussion
Inspection of the time course of the serum lipid changes ( fig. 2) indicates that the full effect of Su-13437 on serum lipids was manifest within 3 weeks after administration of the drug was begun. During the remaining Circulation, Volume XLII, November 1970 27 weeks of drug administration there was no further reduction of serum lipid levels, nor was there any developing tolerance or other lessening of effect on lipids. In view of this plateau of Su-13437 effect on serum cholesterol it is not unexpected that the mean reduction of 22% observed in this 30-week study is very similar to that noted in our preliminary 8week study2 and in the 4-week study of Weiss and co-workers. 4 In this small series the serum cholesterol responses of the several types of hyperlipoproteinemia were very similar. The mean reduction was 22.4% in the six subjects with type II, 19.1% in the single type III patient, and 23.7% in the three subjects with type IV hyperlipoproteinemia.
In all reported studies the effect of Su-13437 on elevated serum triglycerides was even greater than on cholesterol.24 In our study serum triglyceride of the five hypertriglyceridemic patients was reduced by a mean of 51%. Weiss and associates4 observed a decrease of 68% in their 10 subjects who had appreciably higher pretreatment triglyceride levels and also received a higher maximal dose of the drug (600 mg/day). Comparison of serum cholesterol and triglyceride levels during treatment with Su-13437, 400 mg/day, with the levels during treatment with ethyl cholorophenoxyisobutyrate (CPIB), 2 g/day. The mean level observed in each subject during treatment with Su-13437 in the present study is compared with the level observed during a prior period of treatment with CPIB.
nl The significance of the elevated levels of SGOT and SGPT observed in two of the 10 subjects remains in doubt. That this response is perhaps dose related is suggested by its occurrence in two of the three subjects weighing less than 125 pounds and in none of the seven with body weights above this figure. Bianchine and associates9 reported that following administration of Su-13437 labeled with 14C in the carboxyl position the serum half-life of radioactivity was 135 min and that approximately half of the administered radioactivity appeared in the urine, largely as an unidentified metabolite of the drug excreted within the first 24 hours. These observations do not exclude the possibility, however, that accumulation of some other metabolite with a longer half-life may be responsible for the delayed rise in SGOT and
SGPT.
A transient elevation of SGOT levels has been reported to occur in some patients during the early weeks of treatment with CPIB.10 The return to pretreatment levels of the SGOT despite continued administration of the drug and the lack of any other evidence of toxicity have been cited as evidence that this represents an adaptive response of the liver to the drug rather than liver injury." Whatever the exact mechanism of these serum enzyme changes produced by CPIB, it seems likely that the increased levels of SGOT and SGPT observed with Su-13437 represent a similar response to this drug. This speculation is supported by the similarities in chemical structure of the two drugs, both being aryloxyisobutyric acids, and by their similar hepatomegalic effect in the rat. 12 Any conclusions regarding the relative effectiveness of Su-13437 and CPIB must be tentative. Although the conditions under which the responses of these patients to CPIB were determined were in general similar to those of this study, they were not identical with regard to either duration of treatment or frequency of observations. Moreover, the sequence of the two drugs was not varied, the trial with CPIB preceding that with Su-13437 in all subjects. It appears that both drugs are effective in reducing elevated levels of serum cholesterol and triglyceride, with Su-13437 being somewhat more active than CPIB in the reduction of hypertriglyceridemia. This similarity in the responses of serum cholesterol to Su-13437 and to CPIB is in conflict with the report of Berkowitz that Su-13437 resulted in "normalization" of serum cholesterol in the majority of subjects with type II hyperlipoproteinemia, many of whom had previously been unresponsive to CPIB.13 In the present study a 30-week period of treatment with Su-13437 did not result in desirable levels of serum cholesterol in either of the type II patients with very high levels of serum cholesterol and tendinous xanthomas. The palmar xanthomas of the single patient with type III hyperlipoproteinemia cleared in response to Su-13437 although serum cholesterol remained considerably elevated during treatment.
